Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6377

Provisional Schedule

Committee meeting 06 November 2024

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Novartis Pharmaceuticals (ruxolitinib)
Others Christie Haematology and Transplant Unit (Manchester)
  Department of Health and Social Care
  King’s College London – Haemato-oncology department
  NHS England
  St James University Hospital Bone Marrow Transplant Department (Leeds Teaching Hospitals Trust)
  University College London Hospitals HSCT Service
Patient carer groups African-Caribbean Leukaemia Trust
  Anthony Nolan
  Aplastic Anaemia Trust
  Blood Cancer UK
  Chronic Myeloid Leukaemia Support Group
  Cianna’s Smile
  Immunodeficiency UK
  Leukaemia Cancer Society
  Leukaemia Care
  Lymphoma Action
  Macmillan Cancer Support
  MDS UK Patient Support Group
  MPS Society
  Myeloma UK
  Sickle Cell and Young Stroke Survivors
  Sickle Cell Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
  The Essenelle Foundation
  UK Thalassaemia Society
Professional groups British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Paediatric Allergy, Immunity and Infection Group (BPAIIG)
  British Society for Genetic Medicine
  British Society for Haematology
  British Society for Immunology
  British Society of Blood and Marrow Transplantation and Cellular Therapy
  British Transplantation Society
  Cancer Research UK
  Neonatal and Paediatric Pharmacists Group
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics and Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Forum on Haemoglobin Disorders
  UK Primary Immunodeficiency Network
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Pfizer (sirolimus)
  Roche Products (mycophenolate mofetil)
  Rosemont Pharmaceuticals (mycophenolate mofetil)
  Teva Pharma (mycophenolate mofetil)
  Tillomed Laboratories (mycophenolate mofetil)
General commentators All Wales Adult Inherited Metabolic Disease Service Cardiff
  All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services – Jehovah’s Witnesses
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  National Services Division
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Cochrane UK
  Genomics England
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Institute for Health Research
  Oxford Biomedical Research Centre


Key events during the development of the guidance:

Date Update
15 April 2024 Invitation to participate
07 March 2024 - 20 March 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6377
07 March 2024 In progress. Scoping commenced.
01 February 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
01 February 2024 The appraisal is expected to start during March 2024 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-April 2024.

For further information on our processes and methods, please see our CHTE processes and methods manual